Model development and preclinical assessment studies conducted by CAPR scientists
are extensively supported by state-of-the-art histopathology, including automated
tissue processing and immunostaining, followed by application of image acquisition
and quantitative analysis techniques. Samples of tissue biopsies, biological fluids
and macromolecules (proteins, nucleic acids, metabolites) are systematically annotated
To implement a transdisciplinary platform in a clinically relevant manner for enhanced
development of novel efficacious drugs and precision therapies, integrating the
strength of a cross-model comparison approach, CAPR launched a collaborative effort
with nationally recognized clinical centers and organizations developing preclinical
approaches in primary patient-derived xenograft (pdx) models – a strategy referred
to as iGXT (integrated GEM models, patient-derived Xenograft, clinical Trials),
applicable both to a broad spectrum of cancer types and to other diseases.
Supported by experienced dedicated project managers, CAPR strives to complete studies
on time and within allocated budgets employing best practices of contemporary project
management during initiation, planning, execution, monitoring, and closing phases
of every project.
Typed the characters seen in the image below to continue.
Sending Mail ...